Jason Conaty

Hogan Lovells

+ Follow Contact

Latest Posts › Drug Pricing

Share:

FDA adds information on Commissioner’s National Priority Voucher program

This week, the U.S. Food and Drug Administration (FDA) posted additional information on its recently announced “Commissioner's National Priority Voucher” (CNPV) program, which will provide up to five vouchers in the program's...more

7/23/2025 / Biologics , Clinical Trials , Drug Approvals , Drug Pricing , Food and Drug Administration (FDA) , Pharmaceutical Industry , Prescription Drugs , Public Health , Regulatory Authority , Regulatory Reform

FDA Commissioner’s National Priority Voucher program comes with questions surrounding implementation

The U.S. Food and Drug Administration (FDA) announced Tuesday a “Commissioner’s National Priority Voucher” (CNPV) program, which will provide a “limited number” of vouchers to sponsors of drug products that are “aligned with...more

6/19/2025 / Clinical Trials , Drug Pricing , Food and Drug Administration (FDA) , New Guidance , New Regulations , Pharmaceutical Industry , Prescription Drugs , Public Health , Regulatory Oversight , Regulatory Reform

Republican FTC renews challenges to Orange Book patent listings

On May 21, 2025 the Federal Trade Commission (FTC) issued renewed warning letters to five companies regarding over 200 allegedly improperly-listed patents in the Food and Drug Administration (FDA)’s Orange Book. Announcing...more

5/27/2025 / Antitrust Violations , Drug Pricing , Enforcement Actions , FDA Approval , FTC Act , Generic Drugs , Hatch-Waxman , Orange Book , Patent Litigation , Pharmaceutical Patents

3 Results

View per page

Page: of 1